Literature DB >> 8912775

Tissue localization of transforming growth factor-beta1 in pulmonary eosinophilic granuloma.

S Asakura1, T V Colby, A H Limper.   

Abstract

Pulmonary eosinophilic granuloma is characterized by infiltration of the lungs with fibronodular lesions containing specialized Langerhans' cells. In some patients, progressive pulmonary fibrosis leads to significant respiratory impairment. Transforming growth factor-beta1 (TGF-beta1) promotes fibrosis by enhancing the synthesis of extracellular matrix components. The role of TGF-beta1 in promoting fibrosis in the setting of pulmonary eosinophilic granuloma is currently unknown. We used immunohistochemistry to evaluate the extent and distribution of TGF-beta1 and the extracellular matrix components type I collagen and decorin, a TGF-beta1-binding proteoglycan. Lung biopsies from 11 patients with pulmonary eosinophilic granuloma were evaluated. In biopsies with active inflammatory lesions containing Langerhans' cells, hyperplastic type 2 pneumocytes and alveolar macrophages within and surrounding the fibronodular lesions contained abundant TGF-beta1. Langerhans' cells were consistently devoid of immunoreactive TGF-beta1. Active inflammatory lesions also exhibited staining for decorin, in a loosely organized distribution. Advanced fibrotic lesions of eosinophilic granuloma, containing minimal inflammatory cells and few or no Langerhans' cells, exhibited weak or absent staining for TGF-beta1 within either hyperplastic type 2 pneumocytes or alveolar macrophages. The fibroconnective tissues of these advanced fibrotic lesions consistently revealed dense staining for decorin. Through their actions on extracellular matrix protein accumulation, TGF-beta1 and the TGF-beta1-binding proteoglycan decorin may modulate fibrotic repair accompanying pulmonary eosinophilic granuloma.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8912775     DOI: 10.1164/ajrccm.154.5.8912775

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  8 in total

Review 1.  Adult pulmonary Langerhans' cell histiocytosis.

Authors:  A Tazi; P Soler; A J Hance
Journal:  Thorax       Date:  2000-05       Impact factor: 9.139

2.  Development of pulmonary Langerhans cell histiocytosis in a patient with established adenocarcinoma of the lung.

Authors:  Or Kalchiem-Dekel; Adina Paulk; Seth J Kligerman; Allen P Burke; Nirav G Shah; Renee K Dixon
Journal:  J Thorac Dis       Date:  2017-12       Impact factor: 2.895

Review 3.  Diffuse Cystic Lung Disease. Part I.

Authors:  Nishant Gupta; Robert Vassallo; Kathryn A Wikenheiser-Brokamp; Francis X McCormack
Journal:  Am J Respir Crit Care Med       Date:  2015-06-15       Impact factor: 21.405

Review 4.  Cigarette smoking and diffuse lung disease.

Authors:  Rajesh R Patel; Jay H Ryu; Robert Vassallo
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  Pulmonary hypertension in pulmonary langerhans cell granulomatosis.

Authors:  Matthias Held; Philipp Schnabel; Arne Warth; Berthold Jany
Journal:  Case Rep Med       Date:  2012-03-13

Review 6.  Pulmonary langerhans cell histiocytosis.

Authors:  Harpreet S Suri; Eunhee S Yi; Gregorz S Nowakowski; Robert Vassallo
Journal:  Orphanet J Rare Dis       Date:  2012-03-19       Impact factor: 4.123

Review 7.  Interstitial fibrosis and growth factors.

Authors:  J A Lasky; A R Brody
Journal:  Environ Health Perspect       Date:  2000-08       Impact factor: 9.031

Review 8.  Alveolar epithelial type II cell: defender of the alveolus revisited.

Authors:  H Fehrenbach
Journal:  Respir Res       Date:  2001-01-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.